The Jordan Food and Drug Administration: A culture of quality and continuous improvement
DOI:
https://doi.org/10.5912/jcb671Keywords:
regulation, pharmacovigilance, substandard pharmaceutical event, quality, safety, bioequivalanceAbstract
In November 2013, the Jordan Food and Drug Administration, in partnership with the Center for Medicine in the Public Interest, held a seminar entitled, “Advancing the Safe Use of Drugs: Enhancing Regulatory Quality Control.†Attendees included members of the JFDA leadership as well as representatives of Jordan’s healthcare community (hospitals, pharmacists, pharmaceutical manufacturers, academics). The seminar began a strategic thinking process aimed at enhancing a regulatory environment that values pharmaceutical manufacturing quality, the importance of stakeholder involvement, the urgent role of pharmacovigilance, and greater harmonization with advanced regulatory practices. The goal was to develop realistic recommendations that can be implemented within existing authorities and resources; that serve the Jordanian public health; and enhance the stature and reputation of the JFDA as a regional reference and a global leader.